- Company
- Promoting the extension of the term of drug patents
- by Kim, Jin-Gu Mar 23, 2023 04:45am
- Previously, patentees could legally extend the duration of a patent unlimitedly, but the government's plan is to promote it up to 'up to 14 years'. According to the pharmaceutical industry on the 21st, the Korean Intellectual Property Office recently prepared an amendment to the Patent Act to reform the system for the duration of drug patent
- Company
- Forxiga's generics will be suspended until the 7th
- by Kim, Jin-Gu Mar 22, 2023 05:47am
- Manufacturing and sales of Dong-A ST's SGLT-2 inhibitor-type diabetes treatment Dapapro are expected to be suspended by early next month. According to the pharmaceutical industry on the 20th, the Seoul Central District Court recently cited AstraZeneca's request for an injunction to prohibit infringement of patent rights filed against Dong-A
- Company
- 10 years of the global launch of K-biosimilars
- by Chon, Seung-Hyun Mar 22, 2023 05:47am
- The cumulative exports of biosimilar products developed by Celltrion and Samsung Bioepis recorded 13 trillion won. Celltrion's Remsima is rapidly expanding its territory 10 years after entering the European market. Celltrion's biosimilars posted cumulative exports of 9 trillion won, and Samsung Bioepis' overseas sales of more than 4 trillion won
- Company
- Dupixent likely to expand reimb to pediatrics from April
- by Eo, Yun-Ho Mar 22, 2023 05:46am
- Reimbursement of the atopic dermatitis treatment ‘Dupixent’ is expected to be expanded for pediatric and adolescent patients from April. According to sources from related industries, Sanofi-Aventis Korea recently concluded a drug price negotiation with the National Health Insurance Service for the low dose (200mg) of Dupixent (dupilumab
- Company
- Patent extension system for drugs to be reorganized…
- by Kim, Jin-Gu Mar 22, 2023 05:46am
- A plan to reorganize the patent term extension system of biopharmaceuticals in a manner similar to those of the US and Europe is being reviewed. In the pharmaceutical industry, it is predicted that if the reorganization plan passes the National Assembly, the patent term of some original drugs will be reduced to about one year. According
- Company
- Pediatric indication becomes key to sales in Korea
- by Moon, sung-ho Mar 21, 2023 05:56am
- The treatment market for pediatric and adolescent patients have grown rapidly last year. In particular, injections for pediatric and adolescent patients have gained much popularity and raised sales in reimbursed and non-reimbursed markets in hospitals and clinics. The transition from the COVID-19 pandemic to an endemic had increased focus on
- Company
- Increasing male infertility
- by Eo, Yun-Ho Mar 21, 2023 05:56am
- As male infertility increases, interest in follicle-stimulating hormone preparations is increasing. So far, women's infertility treatment has been more active than male infertility treatment. 93.4%of the cost of infertility, which was carried out by 2021, was used for female infertility patients, and only 6.6%were used for male infertility pa
- Company
- Pharmaceutical exports continue to be sluggish...
- by Kim, Jin-Gu Mar 20, 2023 05:51am
- Domestic drugs are continuing to show sluggish sales overseas. During the prolonged COVID-19 crisis, Korea enjoyed an uprise in pharmaceutical exports, but due to the nearing endemic, exports are returning to the pre-COVID-19 level. In particular, the sharp drop in exports of COVID-19 vaccines manufactured in Korea affected the decline in Kor
- Company
- Leclaza costs 88 billion won for phase 3 in 3 years
- by Chon, Seung-Hyun Mar 20, 2023 05:51am
- Last year, Yuhan invested a total of 88 billion won in phase 3 clinical trial of Leclaza, a new anti-cancer drug. Yuhan Corporation is challenging the first-line treatment approval based on the efficacy and safety of Leclaza confirmed in clinical trials. According to the Financial Supervisory Service on the 20th, as of the end of last year, Yuha
- Company
- Possibility of passing the drug price reduction Act
- by Kim, Jin-Gu Mar 20, 2023 05:51am
- A sense of crisis in the biopharmaceutical industry is rising as the possibility of passing the 'drug price reduction/refund bill' in the plenary session of the National Assembly is increasing. The pharmaceutical industry is concerned that the amendment will infringe on the right to request a trial as stipulated in the Constitution, and furt
